Palvella Therapeutics, Inc. (PVLA) stock
PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
$144.35−0.25 (-0.17%)
Close on Nov 17, 2026Market cap $2.08BP/E –Yield –
Palvella Therapeutics cash
Cash and short-term investments held at the end of each period.
Palvella Therapeutics's cash was $250.60M at Jun 30, 2026. For fiscal 2025 it was $57.98M, down 30.6% from the year before. Over ten years it grew 7.0% a year on average. The highest annual figure on record is $128.11M in fiscal 2018.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $57.98M | -30.6% |
| FY2024 | Dec 31, 2024 | $83.60M | +216.7% |
| FY2023 | Dec 31, 2023 | $26.40M | -55.4% |
| FY2022 | Dec 31, 2022 | $59.20M | -49.7% |
| FY2021 | Dec 31, 2021 | $117.76M | +67.2% |
| FY2020 | Dec 31, 2020 | $70.44M | -32.4% |
| FY2019 | Dec 31, 2019 | $104.15M | -18.7% |
| FY2018 | Dec 31, 2018 | $128.11M | +76.4% |
| FY2017 | Dec 31, 2017 | $72.63M | +147.4% |
| FY2016 | Dec 31, 2016 | $29.36M | +0.0% |
| FY2015 | Dec 31, 2015 | $29.35M | +58.9% |
| FY2014 | Dec 31, 2014 | $18.47M | +400.7% |
| FY2013 | Dec 31, 2013 | $3.69M | -41.7% |
| FY2012 | Dec 31, 2012 | $6.33M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $250.60M | +255.8% |
| Q1 FY2026 | Mar 31, 2026 | $261.85M | +246.2% |
| Q4 FY2025 | Dec 31, 2025 | $57.98M | -30.6% |
| Q3 FY2025 | Sep 30, 2025 | $63.57M | +227.7% |
| Q2 FY2025 | Jun 30, 2025 | $70.43M | +257.5% |
| Q1 FY2025 | Mar 31, 2025 | $75.63M | +295.9% |
| Q4 FY2024 | Dec 31, 2024 | $83.60M | +216.7% |
| Q3 FY2024 | Sep 30, 2024 | $19.40M | -56.7% |
| Q2 FY2024 | Jun 30, 2024 | $19.70M | -64.1% |
| Q1 FY2024 | Mar 31, 2024 | $19.10M | -60.5% |
| Q4 FY2023 | Dec 31, 2023 | $26.40M | -55.4% |
| Q3 FY2023 | Sep 30, 2023 | $44.80M | -35.8% |
| Q2 FY2023 | Jun 30, 2023 | $54.90M | -32.1% |
| Q1 FY2023 | Mar 31, 2023 | $48.40M | -51.7% |
| Q4 FY2022 | Dec 31, 2022 | $59.20M | -49.7% |
| Q3 FY2022 | Sep 30, 2022 | $69.80M | -44.2% |
| Q2 FY2022 | Jun 30, 2022 | $80.90M | -32.1% |
| Q1 FY2022 | Mar 31, 2022 | $100.30M | +50.1% |
| Q4 FY2021 | Dec 31, 2021 | $117.76M | +67.2% |
| Q3 FY2021 | Sep 30, 2021 | $125.10M | +51.5% |
| Q2 FY2021 | Jun 30, 2021 | $119.10M | +54.3% |
| Q1 FY2021 | Mar 31, 2021 | $66.80M | -23.0% |
| Q4 FY2020 | Dec 31, 2020 | $70.44M | -32.4% |
| Q3 FY2020 | Sep 30, 2020 | $82.60M | -4.2% |
| Q2 FY2020 | Jun 30, 2020 | $77.20M | -22.6% |
| Q1 FY2020 | Mar 31, 2020 | $86.80M | -21.7% |
| Q4 FY2019 | Dec 31, 2019 | $104.15M | -18.7% |
| Q3 FY2019 | Sep 30, 2019 | $86.20M | -37.2% |
| Q2 FY2019 | Jun 30, 2019 | $99.70M | -34.0% |
| Q1 FY2019 | Mar 31, 2019 | $110.80M | -30.6% |
| Q4 FY2018 | Dec 31, 2018 | $128.11M | +76.4% |
| Q3 FY2018 | Sep 30, 2018 | $137.30M | +52.7% |
| Q2 FY2018 | Jun 30, 2018 | $150.98M | +200.0% |
| Q1 FY2018 | Mar 31, 2018 | $159.58M | +188.9% |
| Q4 FY2017 | Dec 31, 2017 | $72.63M | +147.4% |
| Q3 FY2017 | Sep 30, 2017 | $89.92M | +146.0% |
| Q2 FY2017 | Jun 30, 2017 | $50.32M | – |
| Q1 FY2017 | Mar 31, 2017 | $55.24M | – |
| Q4 FY2016 | Dec 31, 2016 | $29.36M | – |
| Q3 FY2016 | Sep 30, 2016 | $36.56M | – |
See a number that looks wrong?